Advanced Biomed Inc.
ADVB
Analytical Summary
Advanced Biomed Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.
3-Year Financial Trajectory
AnnualBullish Indicators
- No bullish signals detected.
Bearish Risks
- Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Jun 30, 2025 10-K ↗ | FY 2024 Jun 30, 2024 10-K ↗ | FY 2023 Jun 30, 2023 10-K ↗ |
|---|---|---|---|
| EPS Growth YoY (%) |
-14.3%
Weak
Weak
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — |
| Net Income Growth YoY (%) |
-17.1%
Weak
Weak
Year-over-year change in net income |
— | — |
| FCF Growth YoY (%) |
-159.3%
Weak
Weak
Year-over-year change in free cash flow |
— | — |
| Metric | FY 2025 Jun 30, 2025 10-K ↗ | FY 2024 Jun 30, 2024 10-K ↗ | FY 2023 Jun 30, 2023 10-K ↗ |
|---|---|---|---|
| Return on Common Equity (%) (%) |
-93.7%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-725%)
|
-167.3%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-1215%)
|
— |
Secondary lens
Benchmark Lens
Compare ADVB against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare ADVB against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for ADVB
No bullish signals detected
Return on Common Equity (%) is in the bottom quartile
Percentile Rankings
How ADVB compares to all companies
Peer Comparison
ADVB vs similar peers
Compare ADVB with peers
Stack ADVB against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 3 years · 12 quarters